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Chemical compounds, especially radioac-
tively tagged ones, which will selectively hind
to tumor cells or some unique constituent
thereof, have long been sought for clinical
purposes. The pigmented melanoma offers in-
teresting possibilities in this respect since the
melanoeyte performs a unique biochemical act,
melanin synthesis (1). The melanin pigment
is thus contained in only a relatively few tis-
sues, among them the pigmented melanoma.
One of the approaches to the problem of
obtaining a selective uptake of radioactivity
in the pigmented melanoma is to employ a
tagged compound which will selectively hind
to preformed melanin. The behavior of eblor-
promazine (CPZ) in this regard has already
been reported (2). For the detection of mela-
noma tissue in situ, however, a gamma emit-
ting isotope is required, and to date we have
been unsuccessful in so labelling CPZ. Another
class of compound, the quinolines, which were
known to bind to melanin, was therefore in-
vestigated.
Potts (3) bad shown that ebloroquine was
bound to choroidal pigment and Bernstein, et
al (4) had found that the retention of this
compound in the eyes of pigmented rats was
proportional to the degree of melanin pig-
mentation of the animals. Sams and Epstein
(5) demonstrated the affinity of melanin for
ehloroquine in tbe pigmented mouse. Since
the iodine analogue of ehloroquine had been
synthesized and studied in the early 1940's
during the O.S.R.D. program on antimalarials
(6), it appeared as a promising candidate for
further investigation.
MATERIAL5 AND METHODS
Iodoquine-"51 and iodoquine-"I were obtained
as the diphosphates from New England Nuclear
Corporation. These had been prepared by exchange
with radioactive iodine from a preparation of
iodoquine (7-iodo-4-(4-diethylamino-1-metbylbu-
tylamino )-quinoline) prepared by Wintbrop Lab-
oratories (lot number LZ-D-181). Radiocbroma-
tography by the supplier showed a single peak in
butanol (120), acetic acid (30), and water (50),
with an R, value of 0.88. The specific activity was
nominally 1 me/mg.
The mouse melanoma employed was a deeply
pigmented transplantable tumor which had been
carried in C311 mice. This tumor appeared spon-
taneously in a C311 mouse several years ago and
has been carried by subcutaneous transplantation
(using the trocar method) in this strain.
Experimental
Todoquine was first obtained with the 1-125
label for the initial studies because its longer
half life (60 days) permitted a greater variety
of studies.
1. In Vitro. A dialysis method was em-
ployed to determine whether iodoquine-mela-
nm binding occurred. Samples (10 mg eneb)
of sepia melanin, calf tbymus DNA, and egg
albumin, were dissolved or suspended in 10 ml
of 0.1 M KCI. Equal amounts (14 tic) of
iodoquine-I-125 were added to each and all
samples were dialyzed against running tap
water at room temperature in a sbaker bath.
Aliquots were withdrawn at successive in-
tervals to follow the rate of diffusion of
radioactivity from the dialysis bags. The re-
sults of this experiment are shown in Figure
1. After approximately six days of dialysis
nearly half of the iodoquine remained in the
dialysis bag containing melanin, presumably
bound to the melanin, and undergoing desorp-
tion with a half life of about nine days. The
data also indicate that a reversible adsorp-
tion to DNA occurs. This had been shown
earlier by Parker and Irwin (7) in the case
of ebloroquine and nucleic acids, and by Cohen
and Fielding for ebloroquine and DNA (8).
It was evident that tbere was no association
between the iodoquine and egg albumin.
2. Mouse Melanoma. The iodoquine-I-125
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was then administered to a group of melanoma
bearing C311 mice, by the intraperitoneal
route. Each mouse received a single dose of 100
jc of the drug, and the mice were then killed
after various periods of time. Tissues were
taken, weighed, homogenized in saline, and
aliquots containing 1 mg (wet weight) of tis-
sue were counted in a gas flow counter. The
tissue levels of radioactivity, at various pe-
riods after administration of radioiodoquine,
are shown in Figure 2. The radioactivities
are expressed as net counts per mm/mg (wet
weight) of tissue and are uncorrected for
counter efficiency. The three tissues showing
the greatest amounts of activity are displayed
separately from those which contained lesser
amounts. It will be noted in the upper graph
that the melanoma showed the greatest spe-
cific radioactivity for the first few days af-
ter drug administration, followed in order by
the liver, and the eye. The eyes were ho-
mogenized whole and the radioactivity is thus
an average, although it is known that the
binding is primarily to the pigmented struc-
tures.
With the exception of the elevated levels in
the liver, these results were in general ac-
cord with the expected behavior of a melanin
binding compound. However, the known phar-
macology of chloroquine (9) involves degra-
dation affecting the side chain of the mole-
cule and hepatic hold-up is not surprising.
In order to follow the longer term behavior
of the drug, a group of nine normal C311 mice
were injected intraperitoneally with 50 cc
each of iodoquine-I-125 and killed at intervals
up to 35 days. The results for the tissue levels
of radioactivity of the eye, liver, and spleen
are shown in Figure 3. The half life for loss
of radioactivity from the eye is estimated to
be of the order of 85 days. The initial rate of
clearance from the liver corresponds to a half
life of about 8½ days.
Iodoquine-I-131 was obtained, and 50 c
was injected intraperitoneally into a mouse
with a large melanoma. This mouse was then
scanned using a clinical scintillation scanning
instrument and the results are shown in Figure
TIME IN DAYS AFTER INJECTION
Fro. 2. Relative tissue distribution of radioac-
tivity in the melanoma mouse after administration
of 1-125 iodoquine intraperitoneally.
TIME IN HOURS
FIG. 1. The retention of radioactivity in the di-
alysis bag is a measure of the binding of the
1-125 tagged iodoquine to the various biopolymers.
At time zero, equal amounts of tagged iodoquine
were added to each dialysis bag which contained
10 mg of the indicated non-diffusible substances.
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4. The scan made 5 hours after i.p. injection
shows the radioactivity to be concentrated
in three regions: the tumor, the liver and
E
E
peritoneal space, and the thyroid. In the
latter, the elevated radioactivity is due to in-
corporation of free iodide ion by the thyroid
gland.
Twenty-three hours later it is seen that ab-
sorption of the drug from the peritoneum is
complete, and labelling is limited to tumor,
liver, and thyroid. Seventy-two hours after
administration, the tumor, liver, and thyroid
are still clearly seen. The radioactivity over
TABLE I
Specific activity of pigmented Dutch rabbit tis-
sues 24 hours after an I.P. dose of 100 pc of io-
doquine -1-13 1.
dpm/mg
Thyroid 24,396
Choroid 1427
Iris—ciliary body 580
Lens 0
Liver 380
Kidney 302
Spleen 203
Submandibular gland 70
Fjo. 4. Gamma ray scan, of a C311 mouse with a large pigmented melanoma at various
times after I.P. administration of 1-131 iodoquinc.
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TIME IN DAYS
Fro. 3. Relative tissue distribution for eye, liver,
and spleen in the normal C311 mouse, following ad-
ministration of 1-125 iodoquine intraperitoneally.
5 hrs•
OOC PM
72 ti
S.
V
/
S
MELANIN BINDING BY IODOQUINE 253
the left abdominal wall probably represents
contamination of skin or fur with the drug
at the time of injection.
In order to study the eye labelling under de-
tailed conditions, a Dutch rabbit with deeply
pigmented eyes was injected with 100 tc of
iodoquine-I-131. Twenty-four hours later the
rabbit was killed and a number of tissues
were dissected out and counted. The results are
shown in Table I.
The high thyroid activity here (and the
visualization of the mouse thyroid in Figure
4) are due to free iodide, primarily that
liberated from the iodoquine during detoxi-
fication. These results are similar to those
of Potts for the case of the chlorpromazine
distribution in rabbit eyes, and are clearly re-
lated to the pigment content of the tissues.
SUMMARY
Studies both in vitro and in vivo demon-
strate the affinity of iodoquine for melanin.
'When this compound is labelled with 'I, it
affords, in principle, a means for remotely de-
termining the localization of pigmented
melanoma tissue by conventional gamma ray
scanning. Since the target tissue for this com-
pound is any melanin containing structure, the
pigmentary tissues of the eye will also accumu-
late radioactivity. From the data available it
appears that the radiation dose to the lens (and
the consequent hazard of cataract formation)
would be less than 10 rads for a dose of one mu-
licurie administered to a patient.
Detection and localization of melanoma-
bound '311-iodoquine has been experimentally
demonstrated in animals.
The work of Counsell, et al. (Jour. Pharm.
Sci. 56: 1042, 1967) 011 radioiodinated quino-
line derivatives, has come to our attention
during revision of the manuscript.
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